Atossa Therapeutics (ATOS) News Today → Democrats Push to Replace Dollar With Digital Coin, Control Currency. (From Monetary Gold) (Ad) Free ATOS Stock Alerts $1.57 -0.04 (-2.48%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 6:15 AM | investorplace.comWall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024May 17 at 2:34 AM | americanbankingnews.comQ2 2024 EPS Estimates for Atossa Therapeutics, Inc. (NASDAQ:ATOS) Lifted by AnalystMay 16 at 8:59 AM | marketbeat.comShort Interest in Atossa Therapeutics, Inc. (NASDAQ:ATOS) Decreases By 7.4%Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the target of a large decline in short interest in April. As of April 30th, there was short interest totalling 11,440,000 shares, a decline of 7.4% from the April 15th total of 12,350,000 shares. Based on an average daily volume of 1,780,000 shares, the days-to-cover ratio is presently 6.4 days.May 16 at 7:51 AM | marketbeat.comAtossa Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:ATOS)Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Analysts at HC Wainwright boosted their Q2 2024 earnings estimates for Atossa Therapeutics in a research note issued on Monday, May 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.05) per shareMay 15 at 7:13 PM | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15 at 9:42 AM | proactiveinvestors.comAtossa Therapeutics gives final dose in breast cancer prevention studyMay 15 at 8:30 AM | globenewswire.comAtossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialMay 15 at 7:31 AM | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPSAtossa Therapeutics (NASDAQ:ATOS - Get Free Report) issued its earnings results on Monday. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02.May 15 at 6:22 AM | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Rating Reiterated by Cantor FitzgeraldMay 15 at 5:36 AM | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Upgraded at StockNews.comMay 15 at 4:36 AM | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $6.00May 15 at 3:11 AM | markets.businessinsider.comAtossa Therapeutics’ Endoxifen Shows Promising Phase 2 Results, Secures Buy RatingMay 14 at 9:51 AM | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Atossa Therapeutics in a research report on Tuesday.May 13, 2024 | msn.comAtossa Therapeutics files for $100M mixed shelf offeringMay 13, 2024 | msn.comATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024May 13, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Given New $6.00 Price Target at HC WainwrightHC Wainwright boosted their price objective on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the company a "buy" rating in a report on Monday.May 13, 2024 | finance.yahoo.comAtossa Therapeutics Inc (ATOS) Q1 2024 Earnings: Aligns with Analyst Projections Amidst ...May 13, 2024 | proactiveinvestors.comAtossa Therapeutics maintains strong cash position while advancing breast cancer therapy in Q1May 13, 2024 | globenewswire.comAtossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | investorplace.comShhh! 3 Secret Penny Stocks Flying Below Wall Street's RadarMay 7, 2024 | proactiveinvestors.comAtossa Therapeutics welcomes updated breast cancer screening guidelinesMay 7, 2024 | globenewswire.comAtossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesApril 29, 2024 | globenewswire.comAtossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenApril 28, 2024 | marketbeat.comShort Interest in Atossa Therapeutics, Inc. (NASDAQ:ATOS) Expands By 17.0%Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 12,350,000 shares, an increase of 17.0% from the March 31st total of 10,560,000 shares. Based on an average daily volume of 1,620,000 shares, the short-interest ratio is presently 7.6 days.April 16, 2024 | insidermonkey.com5 Micro-Cap Healthcare Stocks Insiders Are BuyingApril 16, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $4.00 target price on shares of Atossa Therapeutics in a report on Tuesday.April 15, 2024 | markets.businessinsider.comPromising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer TreatmentApril 15, 2024 | proactiveinvestors.comAtossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drugApril 15, 2024 | globenewswire.comAtossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerApril 13, 2024 | insidertrades.comJonathan Finn Buys 25,000 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) StockApril 11, 2024 | globenewswire.comAtossa to Participate in Noble Capital Markets Emerging Growth Healthcare ConferenceApril 10, 2024 | markets.businessinsider.comAtossa Therapeutics Poised for Growth with Promising Breast Cancer TreatmentApril 10, 2024 | markets.businessinsider.comAtossa Therapeutics: Strong Buy on Promising EVANGELINE Study Results and Z-endoxifen Efficacy PotentialApril 9, 2024 | msn.comAtossa stock climbs 11% on breast cancer drug dataApril 9, 2024 | proactiveinvestors.comAtossa Therapeutics reports positive data from breast cancer treatment trialApril 9, 2024 | globenewswire.comAtossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-EndoxifenApril 4, 2024 | marketbeat.comQ1 2024 Earnings Forecast for Atossa Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:ATOS)Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Research analysts at HC Wainwright dropped their Q1 2024 earnings estimates for shares of Atossa Therapeutics in a report issued on Tuesday, April 2nd. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per sApril 3, 2024 | finance.yahoo.comAtossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive AnalysisApril 3, 2024 | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateApril 3, 2024 | markets.businessinsider.comOptimistic Outlook for Atossa Therapeutics’ Z-endoxifen in Breast Density and Cancer TherapyApril 2, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Posts Earnings ResultsAtossa Therapeutics (NASDAQ:ATOS - Get Free Report) announced its earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter.April 2, 2024 | bizjournals.comPSBJ taking nominations for CFO of the Year through April 5April 1, 2024 | msn.comATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023April 1, 2024 | proactiveinvestors.comAtossa Therapeutics sets sights on breast cancer trial results after strong quarter of clinical milestonesApril 1, 2024 | globenewswire.comAtossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateMarch 31, 2024 | marketbeat.comAtossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Increase in Short InterestAtossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 8,480,000 shares, a growth of 18.6% from the February 29th total of 7,150,000 shares. Based on an average daily trading volume, of 941,700 shares, the short-interest ratio is presently 9.0 days.March 28, 2024 | bizjournals.comIntroducing the Inno Madness BracketMarch 20, 2024 | proactiveinvestors.comAtossa Therapeutics' breast cancer drug milestone sparks investor enthusiasmMarch 19, 2024 | bizjournals.comAtossa Therapeutics back in Nasdaq's good gracesMarch 19, 2024 | proactiveinvestors.comAtossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using (Z)-endoxifen Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Tomorrow night's deadline (Ad)MarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $200 off your 2024 subscription. Free for 30 days. Start Your Risk-Free Trial Here ATOS Media Mentions By Week ATOS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATOS News Sentiment▼0.680.54▲Average Medical News Sentiment ATOS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATOS Articles This Week▼252▲ATOS Articles Average Week Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OVID News RENB News GBIO News OMER News RIGL News MACK News GALT News TRVI News GTHX News LFCR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATOS) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
